Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TMC647055 + telaprevir is a **combination therapy** developed for the treatment of chronic hepatitis C virus (HCV) infection. **TMC647055** is a potent, selective, nonnucleoside small-molecule inhibitor of the HCV NS5B RNA-dependent RNA polymerase, binding to the NNI-1 allosteric site, thus inhibiting viral RNA replication. **Telaprevir** is a small-molecule inhibitor of the HCV NS3/4A protease, which is critical for viral polyprotein processing and RNA replication. This combination targets two different steps in the HCV replication cycle and is being investigated for synergistic antiviral efficacy and suppression of resistant viral mutations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TMC647055 + telaprevir.